NCT00520403View on ClinicalTrials.gov

A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Renal Cell Cancer
Interventions
DRUG

bevacizumab [Avastin]

15mg/kg iv every 3 weeks

DRUG

Interferon alfa-2a

3 MioIU sc escalating to 18 MioIU sc, 3 times weekly

DRUG

Vinblastine

0.1mg/kg iv every 3 weeks

Trial Locations (16)

10117

Berlin

10967

Berlin

24105

Kiel

28277

Bremen

30449

Hanover

34125

Kassel

39120

Magdeburg

60596

Frankfurt

70174

Stuttgart

86058

Rehling

91052

Erlangen

92637

Weiden

06846

Dessau

06097

Halle

07743

Jena

04103

Leipzig

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00520403 - A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer. | Biotech Hunter | Biotech Hunter